Welcome to our dedicated page for CHEMED SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chemed Corporation filings document a Delaware operating company whose capital stock trades on the NYSE under CHE and whose business is conducted through VITAS Healthcare and Roto-Rooter. Current reports disclose segment operating results for hospice and palliative care services, plumbing and drain cleaning services, patient-care metrics, service revenue and capital allocation.
Chemed's regulatory record also includes 8-K disclosures for earnings releases, Regulation FD updates, senior secured revolving credit facilities and related direct financial obligations. Proxy materials cover director elections, executive compensation, pay-versus-performance data and governance matters, while event reports record leadership changes within the VITAS business.
Chemed Corp executive Brian C. Judkins, VP and Chief Legal Officer, exercised stock options covering 6,786 shares of capital stock at an exercise price of $445.35 per share. The options, which vest in three equal annual installments beginning 10/28/2022, now leave him with 31,281 option-based shares outstanding. To fund the option purchase and related tax obligation, 5,878 shares of capital stock were delivered or withheld at $548.96 per share.
Chemed Corp executive Joel L. Wherley, CEO of Vitas Healthcare, exercised stock options for 2599.0000 shares of capital stock at $445.3500 per share on 2026-08-05. The options, vesting in three equal annual installments commencing 10/28/2022, were fully exercised, leaving him with 30220.0000 direct shares. In a related transaction, 2270.0000 shares of capital stock at $542.6200 per share were withheld to cover the purchase price and tax obligation on the option exercise.
Chemed Corp president and CEO Kevin J. McNamara reported an option exercise and related share dispositions. He exercised stock options for 2,001 shares at $445.35 and sold 2,000 shares of capital stock at a weighted average $539.51. An additional 19,802 shares were withheld to pay the option purchase price and related tax obligations. After the derivative transaction, he directly held 264,158 stock options.
Chemed Corporation has a holder preparing to sell 2,000 shares of common stock through Merrill Lynch, with the shares listed on the NYSE. The planned sale has an aggregate market value of $1,064,500, compared against 13,069,961 shares outstanding.
The seller previously acquired Chemed stock through stock awards and related stock exercises, including 1,656 shares tied to a transaction dated May 2, 2023 and 344 shares tied to a transaction dated August 3, 2023.
Chemed Corp director Patrick P. Grace reported a sale of 190 shares of Capital Stock on 2026-07-31 at $532.00 per share in an open market or private transaction. After this sale, he directly owns 3,533 shares of Chemed stock. The filing does not indicate that this trade was made under a Rule 10b5-1 trading plan.
Chemed Corporation insider Patrick P. Grace has filed to potentially sell capital stock under a Form 144. The filing lists a planned sale of 223 shares of capital stock, with an aggregate market value of $119,258, to be sold through J.P. Morgan Securities LLC on or after July 31, 2026 on the NYSE.
The form also notes that during the prior three months, Grace sold 60 shares of capital stock on May 10, 2026 for total proceeds of $25,547. The securities relate to director compensation.
Chemed Corporation reported second quarter 2026 service revenues and sales of 673,251 thousand, up from 618,798 thousand a year earlier. Net income was 67,703 thousand versus 52,493 thousand, with diluted EPS of $5.13 compared with $3.57. For the first six months, service revenues and sales were 1,330,764 thousand and net income 134,005 thousand, producing diluted EPS of $9.97 versus $8.43.
The VITAS hospice segment generated second quarter service revenues and sales of 443,341 thousand, while Roto-Rooter contributed 229,910 thousand. Segment income from operations was 73,709 thousand for VITAS and 37,232 thousand for Roto-Rooter, offset by a 21,737 thousand corporate loss. Effective tax rates were 25.9% for the quarter and 25.6% year-to-date, close to prior-year levels.
Operating cash flow for the first half of 2026 was 173,032 thousand. Investing cash outflows of 66,027 thousand included 33,540 thousand for business combinations and 32,639 thousand of capital expenditures. Financing activities used 141,298 thousand, largely from 287,521 thousand of share repurchases and 16,049 thousand of dividends, alongside 140,000 thousand of long-term debt, leaving cash at 40,222 thousand.
Chemed Corporation reported stronger Q2 2026 results, with service revenues and sales of $673,251 thousand and net income of $67,703 thousand, or $5.13 per diluted share, up from $3.57 a year earlier. Adjusted diluted EPS rose to $6.06 from $4.27.
VITAS net revenue increased 11.9% to $443.3 million, driven by higher days-of-care, modest Medicare reimbursement increases, sharply lower Medicare Cap billing limitations, and 9.0% higher admissions. Roto-Rooter revenue grew 3.3% to $229.9 million, with gross margin improving to 50.4%.
On this performance and substantial share repurchases, Chemed raised full-year 2026 adjusted EPS guidance to $25.00–$25.75 per diluted share, compared with prior guidance of $24.00–$24.75; the midpoint is 17.8% above 2025 adjusted EPS of $21.55.
Chemed Corp director Andrea R. Lindell reported an open-market sale of 1,347 shares of Capital Stock at $447.33 per share. After this transaction, Lindell directly holds 4,578 shares. This filing reflects a discretionary sale by a board member rather than a compensation-related award.
Chemed Corp director George J. Walsh III reported an open-market sale of company stock. He sold 500 shares of Chemed capital stock at a price of $437.83 per share. After this sale, he continues to hold 3,209 shares directly and 434 shares indirectly through his spouse.